- Conditions
- Allergic Conjunctivitis
- Interventions
- CsA high dose, CsA low dose, PA, Placebo
- Drug
- Lead sponsor
- Fovea Pharmaceuticals SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 716 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 365
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Allergic Conjunctivitis
- Interventions
- SPARC1102 I, SPARC1102 II, SPARC1102 III, Vehicle
- Drug
- Lead sponsor
- Sun Pharma Advanced Research Company Limited
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Primary Open-angle Glaucoma (POAG), Ocular Hypertension
- Interventions
- SHP639 (n=60), Placebo Comparator (n=24)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Dry Eye Disease
- Interventions
- Lifitegrast, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Artesia, California + 33 more
- Conditions
- Dry Eye Disease
- Interventions
- OK-101, Placebo
- Drug
- Lead sponsor
- Okyo Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more
- Conditions
- Atopic Conjunctivitis
- Interventions
- Cyclosporine Vehicle, Cyclosporine 0.010%
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Bakersfield, California
- Conditions
- Presbyopia
- Interventions
- Pilocarpine HCl, Vehicle
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 40 Years to 55 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 23
- States / cities
- Bakersfield, California • Glendale, California • Inglewood, California + 19 more
- Conditions
- Dry Eye Disease
- Interventions
- PL9643 Ophthalmic Solution, Placebo Ophthalmic Solution
- Drug
- Lead sponsor
- ORA, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 4
- States / cities
- Andover, Massachusetts • Raynham, Massachusetts • Shelby, North Carolina + 1 more
- Conditions
- Conjunctivitis, Allergic
- Interventions
- alcaftadine 0.25% ophthalmic solution, olopatadine 0.2% ophthalmic solution, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Dry Eye
- Interventions
- doxycycline, placebo
- Drug
- Lead sponsor
- Alacrity Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Presbyopia
- Interventions
- Pilocarpine Ophthalmic administered with the Optejet dispenser, Placebo administered with the Optejet dispenser
- Combination Product
- Lead sponsor
- Eyenovia Inc.
- Industry
- Eligibility
- 40 Years to 55 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- San Diego, California • Fairfield, Connecticut • Louisville, Kentucky + 6 more
- Conditions
- Dry Eye, Graft-versus-host-disease, Ocular Discomfort
- Interventions
- CAM-101 10%, Vehicle Control, CAM-101 30%
- Biological
- Lead sponsor
- Cambium Bio Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
- Conditions
- Dry Eye
- Interventions
- Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose, Corticosteroid Eye Drop
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Hoffman Estates, Illinois • Yorkville, Illinois • Salt Lake City, Utah
- Conditions
- Allergic Conjunctivitis
- Interventions
- TL-925, Placebo
- Drug
- Lead sponsor
- Telios Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Smyrna, Tennessee
- Conditions
- Infantile Hemangioma, Very Low Birth Weight Infants
- Interventions
- topical 0.5% Timolol maleate, Control (placebo) group
- Drug
- Lead sponsor
- Alice K. Gong
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Progressive Keratoconus
- Interventions
- NXL Energy 1, NXL Energy 2, NXL Energy 3, Sham Treatment
- Combination Product
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Dothan, Alabama • Teaneck, New Jersey • Westerville, Ohio
- Conditions
- Conjunctivitis, Allergic
- Interventions
- Olopatadine, Fluticasone, Saline, Artificial tears
- Drug
- Lead sponsor
- Greiner, Jack V., OD DO PhD
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- North Andover, Massachusetts
- Conditions
- Dry Eye Disease
- Interventions
- Lifitegrast, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 23
- States / cities
- Artesia, California • Hemet, California • Laguna Hills, California + 20 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- Dexamethasone 0.1% ophthalmic suspension, Olopatadine hydrochloride 0.1% ophthalmic solution, Inactive ingredients, used as placebo
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Thyroid Eye Disease, Graves' Orbitopathy
- Interventions
- Teprotumumab, Placebo
- Biological · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 9
- States / cities
- Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 6 more
- Conditions
- Ocular Hypertension
- Interventions
- Latanoprostene Bunod, Placebo
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Anesthesia, Local
- Interventions
- AG-920, Placebo
- Drug
- Lead sponsor
- American Genomics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Allergic Conjunctivitis
- Interventions
- TL-925, Placebo
- Drug
- Lead sponsor
- Telios Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Sjogren's Syndrome
- Interventions
- Placebo, Nipocalimab, Standard of Care Treatment
- Other · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 25
- States / cities
- Anniston, Alabama • Glendale, Arizona • Mesa, Arizona + 21 more